摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-(3,4-diamino-phenoxy)-pyridine-2-carboxylic acid methylamide | 485841-49-4

中文名称
——
中文别名
——
英文名称
4-(3,4-diamino-phenoxy)-pyridine-2-carboxylic acid methylamide
英文别名
4-[(3,4-diaminophenyl)oxy]-N-methylpyridine-2-carboxamide;4-(3,4-diaminophenoxy)-N-methylpyridine-2-carboxamide
4-(3,4-diamino-phenoxy)-pyridine-2-carboxylic acid methylamide化学式
CAS
485841-49-4
化学式
C13H14N4O2
mdl
——
分子量
258.28
InChiKey
AFPAUXGZVJBVCO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    518.4±50.0 °C(Predicted)
  • 密度:
    1.303±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    19
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    103
  • 氢给体数:
    3
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted benzazoles and methods of their use as inhibitors of Raf kinase
    申请人:——
    公开号:US20040122237A1
    公开(公告)日:2004-06-24
    New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    提供了新的替代苯唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新化合物组合物可以单独使用,也可以与至少一种额外药物结合,用于治疗由Raf激酶介导的疾病,如癌症。
  • [EN] FUSED AZOLES SUCH AS 2,5-DISUBSTITUTED BENZIMIDAZOLES, BENZOXAZOLES AND BENZOTHIAZOLES AS KINASE INHIBITORS<br/>[FR] AZOLES FUSIONNES TELS QUE BENZIMIDAZOLES, BENZOXAZOLES ET BENZOTHIAZLES 2,5-DISUBSTITUES COMME INHIBITEURS DE KINASE
    申请人:AMGEN INC
    公开号:WO2004085425A1
    公开(公告)日:2004-10-07
    The invention relates to compounds of the formulae (I) to (III) wherein the substituents are as defined in the specification. These compounds have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity. Accordingly, the compounds of the formulae (I) to (III) would be useful in the prevention and treatment of angiogenesis related disorders, ophthalmological conditions, proliferative diseases, inflammatory diseases, and other pathological conditions as described in the specification.
    这项发明涉及式(I)至(III)的化合物,其中取代基如规范中所定义。这些化合物具有激酶抑制活性,如VEGFR/KDR抑制活性。因此,式(I)至(III)的化合物在预防和治疗与血管生成相关的疾病、眼科疾病、增生性疾病、炎症性疾病以及规范中描述的其他病理状况中将会有用。
  • Indazole benzimidazole compounds
    申请人:Chiron Corporation
    公开号:US20030207883A1
    公开(公告)日:2003-11-06
    Organic compounds having the structure I are provided where the variables have the values described herein. 1 Pharmaceutical formulations and medicaments include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compound or a pharmaceutically acceptable salt of the organic compound with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation or medicament according to the invention to a patient in need thereof.
    提供具有结构I的有机化合物,其中变量具有所述的值。1药物制剂和药物包括该有机化合物或其药学上可接受的盐和药学上可接受的载体,并可通过将该有机化合物或其药学上可接受的盐与载体和水混合制备。治疗患者的方法包括向需要该药物的患者施用本发明的药物制剂或药物。
  • Heterocyclic compounds and methods of use
    申请人:——
    公开号:US20040209892A1
    公开(公告)日:2004-10-21
    Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    选定的化合物对于预防和治疗血管生成介导的疾病等疾病有效。本发明涵盖了新颖的化合物、类似物、前药和其药学上可接受的盐、药物组合物以及预防和治疗癌症等疾病和其他疾病或病况的方法。本发明还涉及制备这些化合物的过程以及在这些过程中有用的中间体。
  • Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
    申请人:——
    公开号:US20040087626A1
    公开(公告)日:2004-05-06
    New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    提供了新的取代苯并咪唑化合物、组合物和抑制人类或动物主体中Raf激酶活性的方法。这些新的化合物组合物可以单独使用或与至少一种其他药物联合使用,用于治疗Raf激酶介导的疾病,如癌症。
查看更多